Abstract
Objectives The main objective of the study was to formulate and evaluate Ranolazine nanosuspension. Ranolazine is an oral anginal medication that belongs to Biopharmaceutics Classification System BCS Class II with low solubility and enters hepatic circulation.Methods Nanoedge technology was used to prepare the Ranolazine nanosuspension. Various characterization studies including drug content yield Fourier Transform Infrared Spectroscopy FT-IR Differential Scanning Calorimetry DSC Scanning electron microscopy SEM and in vitro drug release were carried out. HPMC E15 Eudragit L100 were used as stearic stabilizers lecithin as an electrostatic stabilizer Tween 80 as a surfactant ethanol as the solvent and water as the antisolvent.Result Based on the dissolution study the F3 formulation containing HPMC E15 as the stabilizer was considered the ideal formulation exhibiting a maximum drug release of 84.02 at 60 minutes.Conclusion FTIR and DSC studies indicated good compatibility within the dispersion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Rajiv Gandhi University of Health Sciences Journal of Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
